News platforms as important as content, study claims

Share this article:

Health marketing communications firm Enspektos did a deep dive into desktop and media habits and found that who you are in the healthcare industry determines  how much you trust the information that pops up on the screen.

The overall trend was that doctors, nurses and pharmacists overwhelmingly trust information from health websites accessed from desktops more than information obtained via mobile and social network platforms, and they consider news from the Twitterverse to be the least credible. The study found that 78% of polled doctors trusted websites, compared with 69% of nurses and 71% of pharmacists, yet for all three professions, 85% of the polled individuals said they frequently tap the web for medical information.

Mobile content had credibility among 70% of the polled doctors, 46% of the nurses and 61% of the pharmacists, while health information on social networks was considered credible among 10% of the polled docs,  9% of the nurses and 6% of the pharmacists.

The relatively low fondness for social media, however, does not mean that pharma should continue to stay away from the communal space—the report found that these same healthcare providers changed their minds about the integrity of the social-media news flow if they dipped into the social space while doing work-related web surfing or just after scanning websites for related health information.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.